Tesamorelin vs Sermorelin: Why Full-Length GHRH Achieves Superior Visceral Fat Reduction in Lipodystrophy Models
Tesamorelin, the complete 44-residue GHRH analogue, shows 15% visceral fat reduction in lipodystrophy models where sermorelin does not carry FDA approval. This article examines why full-length structure and N-terminal protection matter.
Read article